Update on Erythropoiesis-Stimulating Agents Administered to Neonates for Neuroprotection.
Journal
NeoReviews
ISSN: 1526-9906
Titre abrégé: Neoreviews
Pays: United States
ID NLM: 101085360
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
entrez:
3
11
2019
pubmed:
5
11
2019
medline:
20
8
2020
Statut:
ppublish
Résumé
Erythropoiesis-stimulating agents (ESAs) such as erythropoietin and darbepoetin have been studied as red blood cell growth factors in preterm and term infants for more than 30 years. Recently, studies have focused on the potential neuroprotective effects of ESAs. In this review, we summarize preclinical animal models and recent clinical trials that provide evidence for ESAs as potential treatments to improve neurodevelopmental outcomes in preterm and term infants.
Identifiants
pubmed: 31676737
pii: 20/11/e622
doi: 10.1542/neo.20-11-e622
doi:
Substances chimiques
Hematinics
0
Neuroprotective Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e622-e635Informations de copyright
Copyright © 2019 by the American Academy of Pediatrics.